Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer

Phase 1 Terminated 13 enrolled Patrick Dillon, MD

RandomizedParallel-groupOpen-labelTreatment

Summary

This pilot study evaluates the use of high-intensity focused ultrasound (HIFU) combined with pembrolizumab in patients with metastatic breast cancer. One-half of participants will be randomized to receive the first dose of pembrolizumab after HIFU and one-half of participants will be randomized to receive their first dose of pembrolizumab before HIFU.

Timeline

Start: 2017-09-25
Primary completion: 2022-06-01
Completion: 2022-06-17

Outcome

Outcome not reported

Stopped (Enrollment): “Low rate of enrollment”

Publications

Sheybani ND, Witter AR, Thim EA, Yagita H, Bullock TNJ, Price RJ. Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity. J Immunother Cancer. 2020 Aug;8(2):e001008. doi: 10.1136/jitc-2020-001008.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous